Here are six highlights:
1. Medicare, Medicaid, Blue Cross Blue Shield of Michigan, Geisinger, Kaiser Permanente and United Healthcare cover the procedure.
2. Clinical evidence in 40 peer-reviewed publications supports iFuse technology.
3. iFuse is the only available SI joint fusion device in the United States backed by evidence illustrating safety, effectiveness and economic benefits.
4. An Australian surgeon performed the country’s first iFuse procedure on May 3.
5. Surgeons in Israel, Kuwait and Saudi Arabia also performed the countries’ first iFuse procedures in early 2016.
6. iFuse technology is now available in 25 countries.
More articles on devices:
Amedica lowers total debt obligations 47% to $12.9M: 5 key notes
Osiris Therapeutics finds better outcomes with Grafix vs. EpiFix — 5 points
CONMED stock “buy” rating reiterated: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
